July 1st 2024
Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.
June 24th 2024
Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.
A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.
February 27th 2024
Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.
Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.
February 20th 2024
Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.
Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.
February 13th 2024
Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.
Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.
February 8th 2024
A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.
Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.
A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.
December 20th 2023
Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.
March 6th 2023
The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.
The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.
The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.
February 27th 2023
Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).
Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.
February 21st 2023
The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.
A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.